APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 سبتمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

30 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

29 أغسطس 2023 06:58:00 بحسب Nasdaq GlobeNewswire

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

22 أغسطس 2023 16:43:29 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 أغسطس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

31 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

30 يوليو 2023 13:00:40 بحسب Nasdaq GlobeNewswire

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

29 يوليو 2023 14:52:12 بحسب Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

10 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يوليو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

07 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

25 مايو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مايو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

04 مايو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

03 مايو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

27 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

23 أبريل 2023 18:05:00 بحسب Nasdaq GlobeNewswire

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

21 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

17 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire